A Systematic Review Aggregated Data and Individual Participant Data meta-Analysis of Spot Stenting in the Treatment of Lower Extremity Peripheral Arterial Disease

Published:April 05, 2022DOI:


      The treatment of infrainguinal peripheral arterial disease often involves complex lesions requiring stent implantation. It is common knowledge that stent length is a negative predictor for restenosis. We investigated the efficacy and safety of spot stenting for the treatment of femoropopliteal lesions.


      We carried out a systematic review for articles published by December 2021 regarding spot stenting in the treatment of peripheral arterial disease. Primary endpoints included primary patency (PP) and freedom from target lesion revascularization (TLR) 12 months postoperatively. We performed a meta-analysis of aggregate data for PP, TLR and technical success and a subgroup analysis between devices dedicated to spot stenting and conventional devices. Following the individual participant data (IPD) extraction, we performed a 2 stage time to event IPD meta-analysis for PP and TLR. Plotting of hazard estimates was performed by applying the Epanechnikov Kernel function.


      Five studies with 818 patients, 965 lesions and a mean lesion length of 169.2 mm were included. Chronic total occlusions comprised 51.7% of the treated lesions while, 80% of the lesions involved the popliteal artery. The pooled PP 12 months post-operatively is 80.72% (95% confidence interval [CI]: 77.67–83.45) (I2 = 36%), 95% prediction interval (PI) (67.94–89.00). The subgroup analysis between devices dedicated to spot stenting and conventional devices produced similar results of 80.93% (95% CI: 77.17–84.19) (I2 = 0%) and 80.30% (95% CI: 74.72–84.90) (I2 = 62%), respectively. The pooled TLR rate is 13.06% (95% CI: 10.69–15.86) (I2 = 53%). The pooled technical success rate is 98.77% (95% CI: 97.50–99.40) (I2 = 18%). The IPD meta-analysis produced statistically significant results favoring spot stenting over long stenting for both primary endpoints. Primary patency hazard ratio (HR) 2.04. (95% CI: 1.25–3.32) (I2 = 0%, t2 = 0). TLR, HR 1.97 (95% CI: 1.02–3.79) (I2 = 0%, t2 = 0). Plotting of hazard estimates produced diametrically opposite courses for the spot and long stenting curves. The hazards cross over at about 6 months, and at about 10 months when long stenting group faces the highest risk for loss of patency, spot stenting hazard reaches near zero values. The curves for TLR portray similar findings.


      Spot stenting is a safe and effective strategy for the treatment of femoropopliteal arterial disease with acceptable short and mid-term primary patency and freedom from TLR rates. Long stenting of the femoral artery doubles the risk of patency loss and TLR compared to spot stenting. The risk of patency loss and TLR in femoral artery spot stenting appears 4 months after the intervention and reaches near zero values at 8 months.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Annals of Vascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aboyans V.
        • Ricco J.B.
        • Bartelink M.E.L.
        • et al.
        Editor's Choice - 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS).
        Eur J Vasc Endovasc Surg. 2018; 55: 305-368
        • Kobayashi N.
        • Hirano K.
        • Yamawaki M.
        • et al.
        Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease.
        J Vasc Surg. 2018; 67: 1151-1158
        • Fujihara M.
        • Takahara M.
        • Sasaki S.
        • et al.
        Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease.
        J Endovasc Ther. 2017; 24: 367-375
        • Thieme M.
        • Von Bilderling P.
        • Paetzel C.
        • et al.
        The 24-month results of the Lutonix Global SFA registry: worldwide experience with Lutonix drug-coated balloon.
        JACC Cardiovasc Interv. 2017; 10: 1682-1690
        • Armstrong E.J.
        • Brodmann M.
        • Deaton D.H.
        • et al.
        Dissections after infrainguinal percutaneous transluminal angioplasty: a systematic review and Current state of clinical evidence.
        J Endovasc Ther. 2019; 26: 479-489
        • Laird J.R.
        • Katzen B.T.
        • Scheinert D.
        • et al.
        Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.
        J Endovasc Ther. 2012; 19: 1-9
        • Soga Y.
        • Takahara M.
        • Iida O.
        • et al.
        Relationship between primary patency and lesion length following Bare nitinol stent placement for femoropopliteal disease.
        J Endovasc Ther. 2015; 22: 862-867
        • Nolan B.W.
        • De Martino R.R.
        • Stone D.H.
        • et al.
        Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass.
        J Vasc Surg. 2011; 54 (discussion 735-6): 730-735
        • Page M.J.
        • McKenzie J.E.
        • Bossuyt P.M.
        • et al.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        BMJ. 2021; 372: n71
        • Guyot P.
        • Ades A.E.
        • Ouwens M.J.N.M.
        • et al.
        Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
        BMC Med Res Methodol. 2012; 12: 9
        • Amendt K.
        • Zeller T.
        • Proczka R.
        • et al.
        Provisional focal stenting of complex femoropopliteal lesions using the Multi-LOC multiple stent delivery system - 12-month results from the LOCOMOTIVE EXTENDED study.
        Vasa. 2021; 50: 209-216
        • Hong S.J.
        • Ko Y.G.
        • Shin D.H.
        • et al.
        Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery.
        JACC Cardiovasc Interv. 2015; 8: 472-480
        • Ko Y.G.
        • Ahn C.M.
        • Rha S.W.
        • et al.
        Comparison of spot versus long stenting for femoropopliteal artery disease.
        Ann Vasc Surg. 2019; 58: 101-107
        • Geraghty P.J.
        • Adams G.L.
        • Schmidt A.
        • et al.
        Twelve-month results of Tack-Optimized balloon angioplasty using the Tack endovascular system in below-the-knee arteries (TOBA II BTK).
        J Endovasc Ther. 2020; 27: 626-636
        • Brodmann M.
        • Wissgott C.
        • Brechtel K.
        • et al.
        Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results.
        J Vasc Surg. 2020; 72: 1636-1647.e1
        • Iida O.
        • Takahara M.
        • Soga Y.
        • et al.
        One-year outcomes of Heparin-Bonded stent-Graft therapy for Real-World femoropopliteal lesions and the association of patency with the Prothrombotic state based on the prospective, observational, multicenter Viabahn stent-Graft placement for femoropopliteal diseases requiring endovascular therapy (VANQUISH) study.
        J Endovasc Ther. 2020; 28: 123-131
        • Tomoi Y.
        • Soga Y.
        • Takahara M.
        • et al.
        Spot stenting versus full coverage stenting after endovascular therapy for femoropopliteal artery lesions.
        J Vasc Surg. 2019; 70: 1166-1176
        • Becquemin J.P.
        • Favre J.P.
        • Marzelle J.
        • et al.
        Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study.
        J Vasc Surg. 2003; 37: 487-494
        • Kasapis C.
        • Gurm H.S.
        Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review.
        Curr Cardiol Rev. 2009; 5: 296-311
        • Ansel G.M.
        • Lumsden A.B.
        Evolving modalities for femoropopliteal interventions.
        J Endovasc Ther. 2009; 16: II82-II97
        • Bausback Y.
        • Wittig T.
        • Schmidt A.
        • et al.
        Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease.
        J Am Coll Cardiol. 2019; 73: 667-679
        • Kokkinidis D.G.
        • Jeon-Slaughter H.
        • Khalili H.
        • et al.
        Adjunctive stent use during endovascular intervention to the femoropopliteal artery with drug coated balloons: Insights from the XLPAD registry.
        Vasc Med. 2018; 23: 358-364
        • Laird J.R.
        • Katzen B.T.
        • Scheinert D.
        • et al.
        Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial.
        Circ Cardiovasc Interv. 2010; 3: 267-276
        • Schillinger M.
        • Minar E.
        Past, present and future of femoropopliteal stenting.
        J Endovasc Ther. 2009; 16: I147-I152
        • Schillinger M.
        • Sabeti S.
        • Dick P.
        • et al.
        Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting.
        Circulation. 2007; 115: 2745-2749
        • Krankenberg H.
        • Schlüter M.
        • Steinkamp H.J.
        • et al.
        Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST).
        Circulation. 2007; 116: 285-292
        • Sabeti S.
        • Schillinger M.
        • Amighi J.
        • et al.
        Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis.
        Radiology. 2004; 232: 516-521
        • Schlager O.
        • Dick P.
        • Sabeti S.
        • et al.
        Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures.
        J Endovasc Ther. 2005; 12: 676-684
        • Bontinis V.
        • Antonopoulos C.N.
        • Bontinis A.
        • et al.
        A systematic review and meta-analysis of Supera interwoven nitinol stents for the treatment of infrainguinal peripheral arterial disease.
        J Cardiovasc Surg (Torino). 2022; (Epub ahead of print)
        • Myint M.
        • Schouten O.
        • Bourke V.
        • et al.
        A real-world experience with the Supera interwoven nitinol stent in femoropopliteal arteries: Midterm patency results and failure analysis.
        J Endovasc Ther. 2016; 23: 433-441
        • Kang S.J.
        • Mintz G.S.
        • Park D.W.
        • et al.
        Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravascular ultrasound analysis.
        Circ Cardiovasc Interv. 2011; 4: 9-14
      1. Point - Counterpoint Coronary stent implantation in long diffuse or focal sequential lesions: full coverage or Spot Stenting?.
        Int J Cardiovasc Intervent. 1998; 1: 113-129
        • Siablis D.
        • Diamantopoulos A.
        • Katsanos K.
        • et al.
        Subintimal angioplasty of long chronic total femoropopliteal occlusions: long-term outcomes, predictors of angiographic restenosis, and role of stenting.
        Cardiovasc Intervent Radiol. 2012; 35: 483-490
        • Tsujimura T.
        • Takahara M.
        • Iida O.
        • et al.
        One-year clinical outcomes following implantation of Innova(TM) self-expanding nitinol stents in patients with peripheral artery diseases presenting femoropopliteal artery lesions.
        J Atheroscler Thromb. 2019; 26: 847-855